Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.
Garcia-Carbonero R (1), Garcia-Figueiras R (2), Carmona-Bayonas A (3), Sevilla I (4), Teule A (5), Quindos M (6), Grande E (7), Capdevila J (8), Aller J (9), Arbizu J (10), Jimenez-Fonseca P 11; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE).
(1) Medical Oncology Department, Hospital Universitario Doce de Octubre, Center affiliated to the Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Av. Cordoba km 5.4, 28041, Madrid, Spain. firstname.lastname@example.org.
(2) Radiology Department, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
(3) Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
(4) Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Hospital Regional Universitario, Málaga, Spain.
(5) Medical Oncology Department, Instituto Catalán de Oncología (ICO), Center affiliated to the Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Seville, Spain.
(6) Medical Oncology Department, Complejo Hospitalario Universitario, A Coruña, Spain.
(7) Medical Oncology Department, Hospital Ramon y Cajal, Madrid, Spain.
(8) Medical Oncology Department, Hospital Vall d'Hebron, Center affiliated to the Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Barcelona, Spain.
(9) Endocrinology Department, Hospital Puerta de Hierro, Madrid, Spain.
(10) Nuclear Medicine Department, Clinica Universidad de Navarra, Navarra, Spain.
(11) Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Magazine: Cancer Metastasis Review
Date: Dec 1, 2015Nuclear Medicine [SP]
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a family of neoplasms with a complex spectrum of clinical behavior. Although generally more indolent than carcinomas, once they progress beyond surgical resectability, they are essentially incurable.
Systemic treatment options have substantially expanded in recent years for the management of advanced disease. Imaging plays a major role in new drug development, as it is the main tool used to objectively evaluate response to novel agents.
However, current standard response criteria have proven suboptimal for the assessment of the antiproliferative effect of many targeted agents, particularly in the context of slow-growing tumors such as well-differentiated NETs.
The aims of this article are to discuss the advantages and limitations of conventional radiological techniques and standard response assessment criteria and to review novel imaging modalities in development as well as alternative cancer- and therapy-specific criteria to assess drug efficacy in the field of GEP-NETs.
CITA DEL ARTÍCULO Cancer Metastasis Rev. 2015 Dec;34(4):823-42. doi: 10.1007/s10555-015-9598-5
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.